At IRBM, we have all the tools necessary to fully characterize your antibody leads. Our assays range from measuring binding kinetic parameters using SPR or BLI, to epitope binning, to cell and tissue specificity measures and in vivo studies of efficacy.
With our deep expertise in identifying and profiling antibodies our team will ensure your therapeutic leads are highly specific and fit-for-purpose.
We’ll fully characterize your antibody in terms of biochemical, functional and pharmacokinetic properties, assess its specificity pattern on tissue by histology, and testing efficacy in vivo in the most aappropriate mouse model.
IRBM’s model systems to test antibodies with therapeutic potential, include cell-derived xenografts, syngeneic mice, humanized mouse models and engineered cell lines expressing bioluminescent reporter genes.
OUR STATE-OF-THE-ART ASSAYS INCLUDE:
Epitope binning
Binding and affinity on target cells: Cell-Based ELISA, FACS analysis
Cell-based functional assays: internalization by IF, ADC, ADCC, CDC, cell toxicity, receptor agonism/antagonism
Tissue specificity by IHC
In vivo studies: MTD, efficacy in Xenograft models, IHC
DISCOVER MORE ABOUT OUR ANTIBODY CHARACTERIZATION ASSAYS
Start a conversation.
Great science begins here.